Simple Summary Glioblastoma (GBM) appears to be a challenging malignancy to
completely eradicate, with few significant improvements in treatment. This review explores …

Glioblastoma (GB) is the most common and most aggressive primary brain tumor in adults,
with an overall survival almost 14.6 months. Optimal resection followed by combined …

Abstract Background and Objective Brain tumors are one of the most common diseases and
causes of death in humans. Since the growth of brain tumors has irreparable risks for the …

Background Glioblastoma is an aggressive brain cancer, usually of unknown etiology, and
with a very poor prognosis. Survival from diagnosis averages only 3 months if left untreated …

Adaptive resistance to conventional and targeted therapies remains one of the major
obstacles in effective management of cancer. Aberrant activation of key signaling …

Context Glioma, the most common primary malignant brain tumour, is a grave health
concern associated with high morbidity and mortality. Current treatments, while effective to …

Glioblastoma multiforme (GBM) is the most malignant and common form of brain cancer in
adults. The molecular mechanisms underlying GBM progression and resistance are …

Chemodynamic therapy (CDT) refers to producing a substantial quantity of reactive oxygen
species (ROS) within tumor tissue using a nanocatalyst based on the Fenton reaction. This …

Glioblastoma is one of the most common primary malignant brain tumors with a poor
prognosis and high mortality rate. Since only small lipophilic molecules can penetrate the …

Glioblastoma is the most aggressive tumor in the central nervous system, with a survival rate
of less than 15 months despite multimodal therapy. Tumor recurrence frequently occurs after …